8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)
Published . Updated .
8-K - Kymera Therapeutics filed an 8-K with the SEC on Oct 29 (a notice of a material company event).
Directly affected
- KYMR Kymera Therapeutics
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Kymera Therapeutics belongs to, so it often moves with news about it.
- AMGN Amgen+18.4% 30d
Amgen is a peer of Kymera Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+16.6% 30d
Gilead Sciences is a peer of Kymera Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- MRNA Moderna+28.2% 30d
Moderna is a peer of Kymera Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- ARGX argenx SE-17.4% 17d
argenx SE is a peer of Kymera Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- RVMD Revolution Medicines
Revolution Medicines is a peer of Kymera Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| KYMR | -9.54% | -6.32% | base | -0.02% | +3.36% | after close | after close |
| XLVNo price data for this ticker | — | — | — | — | — | — | — |
| AMGNNo price data for this ticker | — | — | — | — | — | — | — |
| GILDNo price data for this ticker | — | — | — | — | — | — | — |
| MRNANo price data for this ticker | — | — | — | — | — | — | — |
| ARGXNo price data for this ticker | — | — | — | — | — | — | — |
| RVMDNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Filed: 2026-10-29 AccNo: 0001193125-26-436965 Size: 389 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Price since this story was published: Kymera Therapeutics (KYMR)
| Company | When | Move | Status |
|---|---|---|---|
| Kymera Therapeutics (KYMR) | that day | -0.02% | final price |
| Kymera Therapeutics (KYMR) | the next day | +3.36% | final price |
| Kymera Therapeutics (KYMR) | three days earlier | -6.32% | final price |
| Kymera Therapeutics (KYMR) | five days earlier | -9.54% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 37 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 64 days before publication. Filed 5 Sep 2026. View the filing.
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $1,001 - $15,000 on 12 Aug 2026. That is 78 days before publication. Filed 2 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 80 days before publication. Filed 4 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 35 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 55 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Moderna (MRNA), worth $1,001 - $15,000 on 28 Aug 2026. That is 62 days before publication. Filed 8 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Kymera Therapeutics (KYMR)
Companies mentioned with this story
- KYMR Kymera Therapeutics
In “8-K - Kymera Therapeutics, Inc. (0001815442) (Filer),” Kymera Therapeutics (KYMR) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> KYMR
How “8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)” reaches Kymera Therapeutics (KYMR)
“8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)” (29 Oct 2026) reaches Kymera Therapeutics (KYMR) through this story.
For Kymera Therapeutics (KYMR), the reason on file says SEC 8-K filing -> direct issuer disclosure -> KYMR
Dates and price levels for Kymera Therapeutics (KYMR)
KYMR traded between 117.42 and 127.59 across 2 sessions. The latest close on file is 126.74.
How strong the case is around Kymera Therapeutics (KYMR)
14 out of 100
“8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.